High numbers of tumor-infiltrating FOXP3-positive regulatory T cells are associated with improved overall survival in follicular lymphoma

被引:391
作者
Carreras, Joaquim
Lopez-Guillermo, Armando
Fox, Bridget C.
Colomo, Lluis
Martinez, Antonio
Roncador, Giovanna
Montserrat, Emili
Campo, Elias
Banham, Alison H.
机构
[1] Univ Barcelona, Hosp Clin, Dept Pathol, Hematopathol Sect,IDIBAPS, E-08036 Barcelona, Spain
[2] Univ Barcelona, Hosp Clin, Dept Hematol, Hematopathol Sect,IDIBAPS, E-08036 Barcelona, Spain
[3] Univ Oxford, Nuffield Dept Clin Lab Sci, John Radcliffe Hosp, Oxford, England
[4] CNIO, Madrid, Spain
关键词
D O I
10.1182/blood-2006-04-018218
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The tumor microenvironment plays an important role in the biologic behavior of follicular lymphoma (FL), but the specific cell subsets involved in this regulation are unknown. To determine the impact of FOXP3-positive regulatory T cells (Tregs) in the progression and outcome of FL patients, we examined samples from 97 patients at diagnosis and 37 at first relapse with an anti-FOXP3 monoclonal antibody. Tregs were quantified using computerized image analysis. The median overall survival (OS) of the series was 9.9 years, and the FL International Prognostic Index (FLIPI) was prognostically significant. The median Treg percentage at diagnosis was 10.5%. Overall, 49 patients had more than 10% Tregs, 30 between 5% to 10%, and 19 less than 5%, with a 5-year OS of 80%, 74%, and 50%, respectively (P = .001). Patients with very low numbers of Tregs (< 5%) presented more frequently with refractory disease (P = .007). The prognostic significance of Treg numbers was independent of the FLIPI. Seven transformed diffuse large B-cell lymphomas (DLBCLs) had lower Treg percentages (mean: 3.3%) than FL grades 1,2 (mean: 12.1%) or 3 (mean: 9%) (P < .02). In conclusion, high Treg numbers predict improved survival of FL patients, while a marked reduction in Tregs is observed on transformation to DLBCL.
引用
收藏
页码:2957 / 2964
页数:8
相关论文
共 38 条
  • [1] Outcome in Hodgkin's lymphoma can be predicted from the presence of accompanying cytotoxic and regulatory T cells
    Alvaro, T
    Lejeune, M
    Salvadó, MT
    Bosch, R
    García, JF
    Jaén, J
    Banham, AH
    Roncador, G
    Montalbán, C
    Piris, MA
    [J]. CLINICAL CANCER RESEARCH, 2005, 11 (04) : 1467 - 1473
  • [2] Regulatory T cells in ovarian cancer: Biology and therapeutic potential
    Barnett, B
    Kryczek, I
    Cheng, P
    Zou, WP
    Curiel, TJ
    [J]. AMERICAN JOURNAL OF REPRODUCTIVE IMMUNOLOGY, 2005, 54 (06) : 369 - 377
  • [3] Reduced frequencies and suppressive function of CD4+CD25hi regulatory T cells in patients with chronic lymphocytic leukemia after therapy with fludarabine
    Beyer, M
    Kochanek, M
    Darabi, K
    Popov, A
    Jensen, M
    Endl, E
    Knolle, PA
    Thomas, RK
    von Bergwelt-Baildon, M
    Bebey, S
    Hallek, M
    Schultze, JL
    [J]. BLOOD, 2005, 106 (06) : 2018 - 2025
  • [4] Variation in gene expression patterns in follicular lymphoma and the response to rituximab
    Bohen, SP
    Troyanskaya, OG
    Alter, O
    Warnke, R
    Botstein, D
    Brown, PO
    Levy, R
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2003, 100 (04) : 1926 - 1930
  • [5] B cells and professional APCs recruit regulatory T cells via CCL4
    Bystry, RS
    Aluvihare, V
    Welch, KA
    Kallikourdis, M
    Betz, AG
    [J]. NATURE IMMUNOLOGY, 2001, 2 (12) : 1126 - 1132
  • [6] Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas
    Cheson, BD
    Horning, SJ
    Coiffier, B
    Shipp, MA
    Fisher, RI
    Connors, JM
    Lister, TA
    Vose, J
    Grillo-López, A
    Hagenbeek, A
    Cabanillas, F
    Klippensten, D
    Hiddemann, W
    Castellino, R
    Harris, NL
    Armitage, JO
    Carter, W
    Hoppe, R
    Canellos, GP
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 1999, 17 (04) : 1244 - 1253
  • [7] Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival
    Curiel, TJ
    Coukos, G
    Zou, LH
    Alvarez, X
    Cheng, P
    Mottram, P
    Evdemon-Hogan, M
    Conejo-Garcia, JR
    Zhang, L
    Burow, M
    Zhu, Y
    Wei, S
    Kryczek, I
    Daniel, B
    Gordon, A
    Myers, L
    Lackner, A
    Disis, ML
    Knutson, KL
    Chen, LP
    Zou, WP
    [J]. NATURE MEDICINE, 2004, 10 (09) : 942 - 949
  • [8] Prediction of survival in follicular lymphoma based on molecular features of tumor-infiltrating immune cells
    Dave, SS
    Wright, G
    Tan, B
    Rosenwald, A
    Gascoyne, RD
    Chan, WC
    Fisher, RI
    Braziel, RM
    Rimsza, LM
    Grogan, TM
    Miller, TP
    LeBlanc, M
    Greiner, TC
    Weisenburger, DD
    Lynch, JC
    Vose, J
    Armitage, JO
    Smeland, EB
    Kvaloy, S
    Holte, H
    Delabie, J
    Connors, JM
    Lansdorp, PM
    Ouyang, Q
    Lister, TA
    Davies, AJ
    Norton, AJ
    Muller-Hermelink, HK
    Ott, G
    Campo, E
    Montserrat, E
    Wilson, WH
    Jaffe, ES
    Simon, R
    Yang, LM
    Powell, J
    Zhao, H
    Goldschmidt, N
    Chiorazzi, M
    Staudt, LM
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2004, 351 (21) : 2159 - 2169
  • [10] Analysis of multiple biomarkers, shows that lymphoma-associated macrophage (LAM) content is an independent predictor of survival in follicular lymphoma (FL)
    Farinha, P
    Masoudi, H
    Skinnider, BF
    Shumansky, K
    Spinelli, JJ
    Gill, K
    Klasa, R
    Voss, N
    Connors, JM
    Gascoyne, RD
    [J]. BLOOD, 2005, 106 (06) : 2169 - 2174